Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
2018-03-29
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of tivantinib and topotecan
hydrochloride in treating patients with advanced or metastatic solid tumors. Tivantinib and
topotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.